Cargando…
Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y(1))- and GRP-Receptors—An Improvement for Breast Cancer Imaging?
Heterobivalent peptidic ligands (HBPLs), designed to address two different receptors independently, are highly promising tumor imaging agents. For example, breast cancer has been shown to concomitantly and complementarily overexpress the neuropeptide Y receptor subtype 1 (NPY(Y(1))R) as well as the...
Autores principales: | Vall-Sagarra, Alicia, Litau, Shanna, Decristoforo, Clemens, Wängler, Björn, Schirrmacher, Ralf, Fricker, Gert, Wängler, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161111/ https://www.ncbi.nlm.nih.gov/pubmed/29973529 http://dx.doi.org/10.3390/ph11030065 |
Ejemplares similares
-
Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
por: Judmann, Benedikt, et al.
Publicado: (2020) -
Synthesis, Radiolabeling,
and In Vitro and In Vivo Characterization
of Heterobivalent
Peptidic Agents for Bispecific EGFR and Integrin α(v)β(3) Targeting
por: Braun, Diana, et al.
Publicado: (2023) -
Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin α(v)β(3) and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas?
por: Cheng, Xia, et al.
Publicado: (2021) -
iEDDA Conjugation Reaction in Radiometal Labeling
of Peptides with (68)Ga and (64)Cu: Unexpected Findings
por: Litau, Shanna, et al.
Publicado: (2018) -
Identification of a Suitable Peptidic Molecular Platform for the Development of NPY(Y(1))R‐Specific Imaging Agents
por: Krieger, Korbinian, et al.
Publicado: (2020)